* Says name change effective immediately
* Implements name changes for some compounds
Jan 6 (Reuters) - Antigenics Inc (AGEN.O) said it is changing its name to Agenus Inc, effective immediately, to align itself to its product portfolio of clinical candidates.
The Lexington, Massachusetts-based company said it will continue trading on Nasdaq under the symbol “AGEN.”
Agenus, which has been focusing on developing cancer compounds and treatment for infectious diseases, said it also changed the name of some of its compounds.
The biotechnology company’s investigational herpes vaccine, formerly referred to as AG-707, is now called HerpV. The company’s shares, which have risen 13 percent since it expanded a mid-stage study of a cancer compound in October, were down 4 percent at $1.07 on Thursday on Nasdaq. (Reporting by Vidya L Nathan in Bangalore; Editing by Anne Pallivathuckal)